Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Stroke
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Stroke
    NIH: Simple Blood Test Helps Predict Cardiovascular Disease Risk, Guide Treatment - (DGNews)
    Percutaneous Patent Foramen Ovale Closure Safe for Patients With Thrombophilia: Presented at AHA - (DGDispatch)
    Dual Treatment for Stroke Leads to Improved Recovery Rates, Reduced Mortality - (DGNews)
    TopAbstracts in Stroke 11/13/2008 - (DGNews)
    Nonfasting Triglycerides and Risk of Ischemic Stroke in the General Population - (JAMA)

    News archive

     Recent webcasts/CME - Stroke
    Stroke Prevention and Treatment
    Secondary Prevention of Stroke

    Webcasts/CME archive

     Recent cases - Stroke
      An Echocardiographic-Confirmed Case of Atrial Myxoma Causing Cerebral Embolic Ischemic Stroke: A Case Report
      Diffusion-Negative MRI in Acute Ischemic Stroke: A Case Report
      F-18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for the Diagnosis of Takayasu's Arteritis in Stroke: A Case Report
      Acute Bilateral Anterior Circulation Stroke Due to Anomalous Cerebral Vasculature: A Case Report
      Evolution of Changes in the Computed Tomography Scans of the Brain of a Patient with Left Middle Cerebral Artery Infarction: A Case Report

      Cases archive
        




      my personal edition > stroke > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Atorvastatin Helps Protect Kidneys in SPARCL Patients: Presented at AHA

      By Ed Susman

      ORLANDO, FL -- November 12, 2007 -- Treatment of stroke patients with atorvastatin can preserve kidney function in patients with or without chronic kidney disease, metabolic syndrome, or type 2 diabetes, researchers reported here at the American Heart Association (AHA) 2007 Scientific Sessions.

      In a new post hoc analysis of the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study, doctors scrutinized kidney function based on the glomerular filtration rate (GFR), a standard test of global kidney function.

      Poststroke or mini-stroke patients without chronic kidney disease, with chronic kidney disease, and with metabolic syndrome who were treated with atorvastatin 80 mg demonstrated improved kidney function compared with placebo, the researchers said on November 5.

      "These results are especially significant for poststroke diabetic patients because they are more likely to develop progressive kidney disease," said Vito Campese, MD, Chief, Division of Nephrology/Hypertension, University of Southern California, Los Angeles, California.

      "With atorvastatin we were able to stabilize patients' kidney function, and given the established relationship between progressive kidney disease and cardiovascular outcome, this may contribute to reducing cardiovascular events," he added.

      Among the 2,671 patients without chronic kidney disease, atorvastatin 80 mg significantly improved kidney function compared with placebo, changing the estimated glomerular filtration rate (GFR) during the trial by 2.22 mL/min/1.73 m2 versus 0.22 mL/min/1.73m2 (P <.0001).

      In addition, patients with chronic kidney disease had an increase in GFR of 3.15 mL/min/1.73m2 with atorvastatin compared with 1.82 mL/min/1.73 m2 with placebo (P =.017).

      The atorvastatin arm of the study also saw improvement or stabilization of kidney function in patients with metabolic syndrome and in patients with type 2 diabetes, Dr. Campese said.

      The original SPARCL study, which enrolled 4,731 patients, was published in 2006 (N Engl J Med. 2006;355(6):549-59). The trial is the only study to date to evaluate the benefits of a statin solely in patients with a prior stroke or mini-stroke.

      In the SPARCL study, patients with chronic kidney disease had higher risk of stroke (27%) or major coronary events (70%) compared with patients without chronic kidney disease. In the trial, those with kidney disease significantly reduced their risk of major coronary events by taking atorvastatin.

      In a previous post hoc analysis of the SPARCL trial, there was a higher incidence of hemorrhagic stroke in patients taking atorvastatin 80 mg compared with patients taking placebo. Patients with prior hemorrhagic stroke at study entry appeared to be at an increased risk of hemorrhagic stroke.

      Funding for the SPARCL trial was provided by Pfizer.


      [Presentation title: Effect of High-Dose Atorvastatin on Changes in Renal Function: A Secondary Analysis of the Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) Trial. Abstract 2173]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send